What is HC Wainwright’s Estimate for GANX FY2024 Earnings?

Gain Therapeutics, Inc. (NASDAQ:GANX) – Equities research analysts at HC Wainwright upped their FY2024 earnings per share estimates for shares of Gain Therapeutics in a research report issued on Monday, November 25th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($0.95) for the year, up from their prior estimate of ($1.06). HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Gain Therapeutics’ current full-year earnings is ($1.04) per share. HC Wainwright also issued estimates for Gain Therapeutics’ Q4 2024 earnings at ($0.18) EPS, Q1 2025 earnings at ($0.18) EPS, Q2 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.15) EPS and FY2025 earnings at ($0.68) EPS.

A number of other equities research analysts also recently weighed in on GANX. Chardan Capital reissued a “buy” rating and issued a $6.00 price target on shares of Gain Therapeutics in a report on Friday, August 9th. Oppenheimer restated an “outperform” rating and issued a $8.00 price target on shares of Gain Therapeutics in a research report on Wednesday, August 14th.

Gain Therapeutics Trading Down 4.9 %

Shares of Gain Therapeutics stock opened at $1.73 on Wednesday. The business has a fifty day simple moving average of $2.07 and a 200-day simple moving average of $1.71. Gain Therapeutics has a fifty-two week low of $0.89 and a fifty-two week high of $5.33. The firm has a market cap of $45.88 million, a price-to-earnings ratio of -1.57 and a beta of 0.33. The company has a quick ratio of 2.99, a current ratio of 2.99 and a debt-to-equity ratio of 0.04.

Institutional Trading of Gain Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Warberg Asset Management LLC acquired a new position in shares of Gain Therapeutics in the second quarter worth about $66,000. Renaissance Technologies LLC lifted its position in shares of Gain Therapeutics by 154.2% in the 2nd quarter. Renaissance Technologies LLC now owns 118,700 shares of the company’s stock valued at $152,000 after acquiring an additional 72,000 shares in the last quarter. Geode Capital Management LLC boosted its stake in Gain Therapeutics by 48.0% in the 3rd quarter. Geode Capital Management LLC now owns 271,972 shares of the company’s stock worth $484,000 after purchasing an additional 88,236 shares during the period. Finally, Hohimer Wealth Management LLC purchased a new position in Gain Therapeutics during the 2nd quarter worth approximately $422,000. Institutional investors and hedge funds own 11.97% of the company’s stock.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.